2. Academic Validation
  3. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers

  • Cancer Discov. 2024 Sep 16. doi: 10.1158/2159-8290.CD-24-0887.
Brian Belmontes 1,  Katherine K Slemmons 1,  Chun Su 2,  Siyuan Liu 1,  Antonia N Policheni 3,  Jodi Moriguchi 1,  Hong Tan 1,  Fang Xie 2,  Daniel Andrew Aiello 1,  Yajing Yang 1,  Raul Lazaro 4,  Famke Aeffner 2,  Matthew G Rees 5,  Melissa M Ronan 5,  Jennifer A Roth 5,  Mikkel Vestergaard 6,  Sanne Cowland 6,  Jan Andersson 6,  Ian Sarvary 6,  Qing Chen 1,  Pooja Sharma 1,  Patricia Lopez 1,  Nuria Tamayo 1,  Liping H Pettus 1,  Sudipa Ghimire-Rijal 1,  Susmith Mukund 1,  Jennifer R Allen 1,  Jason DeVoss 2,  Angela Coxon 1,  Jordi Rodon 7,  Francois Ghiringhelli 8,  Nicolas Penel 9,  Hans Prenen 10,  Sanne Glad 6,  Chen-Hua Chuang 2,  Kiana Keyvanjah 11,  Danielle M Townsley 12,  John R Butler 1,  Matthew P Bourbeau 13,  Sean Caenepeel 1,  Paul E Hughes 1
Affiliations

Affiliations

  • 1 Amgen Inc., Thousand Oaks, CA, United States.
  • 2 Amgen (United States), South San Francisco, CA, United States.
  • 3 Walter and Eliza Hall Institute of Medical Research, Australia.
  • 4 Amgen (United States), Thousand Oaks, CA, United States.
  • 5 Broad Institute, Cambridge, MA, United States.
  • 6 Amgen Inc., Copenhagen, Denmark.
  • 7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • 8 Centre Georges François Leclerc, Dijon, France.
  • 9 Centre Oscar Lambret, Lille, France.
  • 10 University Hospital Antwerp, Edegem, Belgium.
  • 11 Amgen Inc, Thousand Oaks, CA, United States.
  • 12 AstraZeneca, Gaithersburg, Maryland, United States.
  • 13 Pfizer (United States), La Jolla, CA, United States.
PMID: 39282709 DOI: 10.1158/2159-8290.CD-24-0887
Abstract

One of the most robust synthetic lethal interactions observed in multiple functional genomic screens has been dependency on PRMT5 in Cancer cells with MTAP deletion. We report the discovery of the clinical stage MTA-cooperative PRMT5 Inhibitor AMG 193, which preferentially binds PRMT5 in the presence of MTA and has potent biochemical and cellular activity in MTAP-deleted cells across multiple Cancer lineages. In vitro, PRMT5 inhibition induces DNA damage, cell cycle arrest, and aberrant alternative mRNA splicing in MTAP-deleted cells. In human cell line and patient-derived xenograft models, AMG 193 induces robust antitumor activity and is well tolerated with no impact on normal hematopoietic cell lineages. AMG 193 synergizes with chemotherapies or the KRAS G12C inhibitor sotorasib in vitro, and combination treatment in vivo significantly inhibits tumor growth. AMG 193 is demonstrating promising clinical activity, including confirmed partial responses in patients with MTAP-deleted solid tumors from an ongoing phase 1/2 study.

Figures
Products